Effects of focused ultrasound on human cervical cancer HeLa cells in vitro
Cervical cancer is the fourth most common malignant tumor in women. Many studies have confirmed that early childbirth, prolificacy, HPV infection, and smoking are some risk factors. This article explored the effects of exposing human cervical cancer HeLa cells to different focused ultrasound intensi...
Gespeichert in:
Veröffentlicht in: | Investigación clínica 2023-11, Vol.64 (4), p.441-450 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | spa |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Cervical cancer is the fourth most common malignant tumor in women. Many studies have confirmed that early childbirth, prolificacy, HPV infection, and smoking are some risk factors. This article explored the effects of exposing human cervical cancer HeLa cells to different focused ultrasound intensities in vitro. The study employed three groups of cells: 1- a high-intensity treated group, 2- a low-intensity treated group, and 3- a control group. Results showed that after 12 hours of focused ultrasound treatment, the growth inhibi-tion rate of the low-intensity group was 55.6% higher than that of the control group, and the growth inhibition rate of the high-intensity group was 41.2% higher than that of the low-intensity group. Therefore, focused ultrasound had a specific inhibitory effect on the growth of HeLa cells, and the higher the intensity of focused ultrasound, the higher the inhibition rate on cancer cells. In addition, the Cycle Threshold (Ct) values of the three groups of cells before treatment were the same, but the Ct values after treatment had changed. The Ct value of the low-intensity group was 18.1% lower than that of the control group, and the Ct value of the high-intensity group was lower than that of the low-intensity group by 27.8%, showing that focused ultrasound can effectively reduce the activity of HeLa cells in vitro. |
---|---|
ISSN: | 0535-5133 2477-9393 |
DOI: | 10.54817/IC.v64n4a01 |